InventisBio Co., Ltd.

New Capabilities

Developer of nomelcitinib (D-2570)

InventisBio said on Nov. 2, 2026 that nomelcitinib met the main and secondary goals of a 391-patient Phase III trial in moderate-to-severe plaque psoriasis. More than 70% of patients on either of two doses reached PASI 90 at week 16, meaning their severity score fell at least 90% from baseline, and more than 80% were rated clear or almost clear. Both results beat placebo with p<0.0001, though the company has not disclosed the placebo rate.

Updated Nov 2